← Eichor
Study identifier: NCT07049926 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Condition: Renal Cell Carcinoma  ·  Sponsor: Merck Sharp & Dohme LLC

PhasePhase 1/Phase 2
Planned participants140
Who can joinAll sexes, 18 Years to 120 Years
Healthy volunteersNo

About this study

Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with clear cell renal cell carcinoma (ccRCC) who have recurrent disease during or after anti-programmed cell death 1/programmed cell death ligand 1 (PD-\[L\]1) adjuvant therapy. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study

This description comes directly from the study's public registry record.

Talk to the study team

Toll Free Number  ·  1-888-577-8839  ·  Trialsites@msd.com

Always discuss trial participation with your own doctor first.

Locations (30)

UCSF Medical Center at Mission Bay ( Site 5008)San Francisco, California, United StatesRecruiting
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5026)Mineola, New York, United StatesRecruiting
Laura and Isaac Perlmutter Cancer Center ( Site 5016)New York, New York, United StatesRecruiting
Memorial Sloan Kettering Cancer Center ( Site 5002)New York, New York, United StatesRecruiting
Duke Cancer Institute ( Site 5015)Durham, North Carolina, United StatesRecruiting
UPMC Cancer Center/Hillman Cancer Center ( Site 5017)Pittsburgh, Pennsylvania, United StatesRecruiting
Vanderbilt University Medical Center ( Site 5004)Nashville, Tennessee, United StatesRecruiting
Centro de Estudios Clínicos SAGA ( Site 6110)Santiago, Region M. de Santiago, ChileRecruiting
Bradfordhill ( Site 6101)Santiago, Region M. de Santiago, ChileRecruiting
C.H.U. de Strasbourg Hopital de Hautepierre ( Site 5203)Strasbourg, Bas-Rhin, FranceRecruiting
Institut Claudius Regaud ( Site 5200)Toulouse, Haute-Garonne, FranceRecruiting
Centre Eugene Marquis ( Site 5205)Rennes, Ille-et-Vilaine, FranceRecruiting

+ 18 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07049926